News Headlines

  1. Zydus Lifesciences Limited Completes The Acquisition Of Agenus Inc.'s Biologics Manufacturing Facilities, Launches Zylidac Bio LLC In The U.S. 1/15/2026

    Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") is an innovation-led life-sciences company with an international presence, today announced the successful closure of the Asset Purchase Agreement, Share Purchase Agreement, and the exclusive Licensing Agreement with Agenus Inc. (NASDAQ: AGEN).

  2. Agno Pharma Acquires Actylis's CDMO Manufacturing Asset, The Legacy Cascade Chemistry Business Based In Eugene, Oregon, Strengthening Agno's US cGMP API Development And Manufacturing Capabilities 1/15/2026

    Agno Pharma, a global contract development and manufacturing organization (CDMO) specializing in small-molecule active pharmaceutical ingredients (APIs) and critical GMP intermediates announced the acquisition of Actylis Eugene, the legacy Cascade Chemistry business based in Eugene, Oregon.

  3. Rakuten Medical And LOTTE Biologics Sign Manufacturing Agreement To Support Biopharmaceuticals In Global Oncology Program 1/14/2026

    Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical’s production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy.

  4. AbbVie To Buy Device Manufacturing Facility From West Pharmaceutical Services 1/14/2026

    The acquisition of the Tempe, Arizona facility will expand U.S.-based drug delivery device capacity and support the company’s $10 billion manufacturing investment.

  5. Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement 1/14/2026

    Fresenius Kabi, an operating company of Fresenius, and TQ Therapeutics, announced today they have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. 

  6. Phlow And Enveda Partner To Advance AI-Driven Chemistry To Accelerate Domestic Pharmaceutical Development And Transform Drug Substance Manufacturing 1/14/2026

    Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active Pharmaceutical Ingredient (API) manufacturing process development in collaboration with Enveda, a biotechnology company that learns from life’s chemistry to create better medicines faster.

  7. ElpasBio And Fosun Kairos Announce Commercialization Collaboration For AlloJoin® Stem Cell Therapy 1/13/2026

    ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, today announced that it has entered into a collaboration agreement with Fosun Kairos for the commercialization of ElpasBio's investigational allogeneic human adipose-derived mesenchymal stem cell (haMPC) therapy, lotazadromcel (trade name AlloJoin®) for the treatment of knee osteoarthritis (KOA) in Mainland China, Hong Kong SAR, and Macau SAR.

  8. GARDP And Debiopharm Partner To Advance Development Of Novel Gonorrhea Drug 1/13/2026

    The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio 1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae.

  9. Tahoe Therapeutics And Alloy Therapeutics To Form Joint Venture And Develop First-In-Class Antibody-Drug Conjugates For Hard-To-Treat Cancers 1/13/2026

    Tahoe Therapeutics and Alloy Therapeutics announced today that they are forming a jointly seeded new company focused on developing first-in-class antibody-drug conjugates (ADCs) for patients with hard-to-treat cancers.

  10. AbbVie To Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities In The United States 1/12/2026

    AbbVie (NYSE: ABBV) and West Pharmaceutical Services (NYSE: WST) announced today a definitive agreement for AbbVie to acquire a device manufacturing facility in Tempe, Arizona and associated intellectual property from West.